Panbela Therapeutics’ (PBLA) “Buy” Rating Reaffirmed at Roth Mkm

Panbela Therapeutics (NASDAQ:PBLA)‘s stock had its “buy” rating reiterated by investment analysts at Roth Mkm in a note issued to investors on Wednesday, March 27th, Benzinga reports.

Panbela Therapeutics Price Performance

Shares of NASDAQ:PBLA opened at $0.55 on Wednesday. Panbela Therapeutics has a 52-week low of $0.41 and a 52-week high of $477.00. The stock’s 50-day simple moving average is $1.15 and its two-hundred day simple moving average is $10.77.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. HRT Financial LP purchased a new position in Panbela Therapeutics in the 1st quarter worth approximately $30,000. Walleye Capital LLC bought a new stake in Panbela Therapeutics in the 2nd quarter worth approximately $217,000. Anson Funds Management LP bought a new stake in Panbela Therapeutics in the 1st quarter worth approximately $72,000. UBS Group AG increased its stake in Panbela Therapeutics by 46,589.5% in the 3rd quarter. UBS Group AG now owns 190,493 shares of the company’s stock worth $51,000 after acquiring an additional 190,085 shares during the last quarter. Finally, Vanguard Group Inc. bought a new stake in Panbela Therapeutics in the 3rd quarter worth approximately $60,000. 4.37% of the stock is owned by hedge funds and other institutional investors.

About Panbela Therapeutics

Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase.